Human Studies
SMS cells are being evaluated in human studies to assess their potential in treating diseases such as:
A scientist in a lab coat looking through a microscope.
A medical room with an x-ray of a person's lungs
Respiratory diseases:
COPD
Bio-manufactured SMS cells are administered via nebulization, enabling direct delivery to the lungs. Their unique size and resilience characteristics make this method of cell delivery feasible and effective. A phase 1 clinical trial is currently enrolling 18 patients with mild to moderate COPD, organized into three ascending-dose cohorts.
The primary endpoint is safety and tolerability, while secondary and exploratory endpoints include early signs of efficacy, such as improvements in lung function, reduction in exacerbation frequency, and enhanced patient-reported outcomes.